Citigroup lowered shares of PTC Therapeutics (NASDAQ:PTCT – Free Report) from a buy rating to a neutral rating in a research note published on Monday, MarketBeat reports. Citigroup currently has $28.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $55.00. Other equities analysts also recently issued research reports about […]
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its target price reduced by Barclays from $44.00 to $26.00 in a report published on Monday morning, Marketbeat Ratings reports. Barclays currently has an equal weight rating on the biopharmaceutical company’s stock. PTCT has been the subject of a number of other research reports. Royal Bank of Canada […]
Phocas Financial Corp. decreased its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 20.8% during the 2nd quarter, Holdings Channel.com reports. The firm owned 80,697 shares of the biopharmaceutical company’s stock after selling 21,203 shares during the period. Phocas Financial Corp.’s holdings in PTC Therapeutics were worth $3,282,000 at the end […]
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its target price decreased by Royal Bank of Canada from $49.00 to $26.00 in a research report sent to investors on Monday morning, Marketbeat Ratings reports. Royal Bank of Canada currently has a sector perform rating on the biopharmaceutical company’s stock. A number of other equities analysts have […]
By Colin Kellaher Shares of PTC Therapeutics fell 21% in premarket trading Friday after the biopharmaceutical company said European approval of its key.